Biomedical Research · us
Beyond Response Rates, Early Cevostamab Trial Reveals the Opportunities and Limits of a New Target in Multiple Myeloma
Complete phase 1 data provide human proof of concept for targeting FcRH5, while also showing weaker efficacy in patients previously treated with BCMA-directed therapy; whether this new pathway can truly expand treatment options remains a question for later-stage trials.
The treatment arsenal for multiple myeloma continues to grow, but the challenge has not disappeared: after repeated relapses, patients often gradually exhaust proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, and even next-generation BCMA-directed therapies may fail. The significance of the phase 1 cevostamab trial lies in its different approach—targeting FcRH5 on the surface of tumor cells in an effort to open another avenue for patients with limited treatment options.
This bispecific antibody binds FcRH5 at one end and CD3 on T cells at the other, bringing immune cells closer to myeloma cells and triggering an attack. The peer-reviewed GO39775 study was a Genentech-sponsored, multicenter, open-label phase 1 trial. Clinical trial registration data show that 355 people were enrolled across different doses and dosing regimens, with treatment administered in 21-day cycles for up to 17 cycles.
In the group receiving the final selected target dose of 160 mg, patients had received a median of six prior lines of therapy, 95.8% were refractory to all three major drug classes, and 73.7% were refractory to five drugs; 57.5% had previously received BCMA-directed treatment. Even though the disease was highly refractory, more than 40% of patients still had a treatment response, with a median duration of response of 11.2 months, providing preliminary human evidence for FcRH5 as a clinical target.
However, the response rate does not fully capture the extent of disease control. In the 160 mg group, median progression-free survival was only 2.8 months overall; it was 5.2 months among those who had not previously received BCMA-directed therapy and 2.1 months among those who had. This difference cannot directly prove that BCMA treatment weakens the effect of cevostamab, because the phase 1 trial was not designed for between-group comparisons, and differences in disease course and prior treatment may also have affected the results. It is better viewed as a signal indicating that subsequent studies must define the appropriate patient population and treatment sequence more carefully.
Safety is also critical to further development. In the 160 mg group, 54.5% of patients developed infections. Although the trial did not reach the maximum tolerated dose, for people who have undergone multiple lines of treatment and already have impaired immune function, the burden of infection cannot be dismissed simply as “manageable.” The researchers ultimately recommended 160 mg every three weeks for phase 2, with three-step dose escalation to reduce risks associated with immune activation.
What cevostamab has shown so far is that FcRH5 warrants continued investigation, not that a new standard of care has already taken shape. This single-arm, early dose-exploration study lacked a control group, included a complex patient population, and could not determine the optimal place of fixed-duration treatment relative to continuous therapy. If subsequent trials are to move from proof of concept to a practical treatment option, they must not only confirm whether the responses can be reproduced, but also address infection risk, the impact of prior BCMA treatment, and where cevostamab should be positioned in the treatment journey.